King Shengtai Pharmaceuticals: The new drug application for HTD1801 has been accepted by the China National Medical Products Administration.

King Saint Tai Pharmaceuticals announced that the China National Medical Products Administration has accepted the new drug application for HTD1801 for the treatment of type 2 diabetes. This is the first new drug application submitted by King Saint Tai Pharmaceuticals, and is also an important milestone for the company's move towards commercialization of products.